90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years

@inproceedings{Casadei201690yttriumibritumomabTC,
  title={90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years},
  author={Beatrice Casadei and Cinzia Pellegrini and Alessandro Pulsoni and Giorgia Annechini and Amalia De Renzo and Vittorio Stefoni and Alessandro Broccoli and Letizia Gandolfi and Federica Quirini and Lorenzo Tonialini and Alice Morigi and Lisa Argnani and Pier Luigi Zinzani},
  booktitle={Cancer medicine},
  year={2016}
}
Radioimmunotherapy (RIT) after an induction phase with conventional chemoimmunotherapy became an attractive strategy of consolidation for patients with advanced follicular lymphoma: in particular, in many studies RIT was represented by yttrium-90-ibritumomab tiuxetan ((90) Y-IT). Independently by the different front-line treatment, updates on the long-term follow-up of these studies are needed because the disease course of follicular lymphoma is characterised by multiple relapses and… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Safety and efficacy of ( 90 ) yttrium - ibritumomab - tiuxetan for untreated follicular lymphoma patients . An Italian cooperative study

  • R. Maglie V. Stefoni
  • Br . J . Haematol .
  • 2013